Matches in SemOpenAlex for { <https://semopenalex.org/work/W2347150527> ?p ?o ?g. }
- W2347150527 endingPage "265" @default.
- W2347150527 startingPage "237" @default.
- W2347150527 abstract "Parkinson’s disease (PD) is normally associated with dopamine and other catecholamines because of the profound loss of dopaminergic neurons in the substantia nigra that is the hallmark of the disease. The need for new therapies to treat symptomatic motor and non‐motor symptoms, along with motor complications such as L‐DOPA‐induced dyskinesias (LIDs), remains an important challenge in drug discovery. Significant progress has been made recently in the development of new non‐dopaminergic treatments in the last few years, and there is substantial evidence for altered glutamate neurotransmission in PD, which may be a consequence of dopamine loss. This has generated a great deal of interest in glutamate receptor modulators for the treatment of PD. The interest initially focused on ionotropic glutamate receptors (iGluRs) both for the treatment of the symptoms of PD as well as for neuroprotective effects, and several NMDA and AMPA receptor antagonists have progressed to clinical trials. More recently, there has been substantial progress in the development of metabotropic glutamate receptor (mGluR) modulators. The recent clinical proof‐of‐concept for the treatment of LIDs with mGluR5 negative modulators has demonstrated the potential clinical significance of this approach, and positive modulators or agonists at mGluR4 also look very promising. In this chapter we will review the development and current status of compounds that modulate iGluRs and mGluRs for the treatment of PD and illustrate the challenges and opportunities that these compounds present." @default.
- W2347150527 created "2016-06-24" @default.
- W2347150527 creator A5024772047 @default.
- W2347150527 creator A5028635849 @default.
- W2347150527 creator A5077624898 @default.
- W2347150527 creator A5085552858 @default.
- W2347150527 creator A5086035382 @default.
- W2347150527 date "2013-07-29" @default.
- W2347150527 modified "2023-09-27" @default.
- W2347150527 title "Glutamate Receptor Modulators as Emergent Therapeutic Agents in the Treatment of Parkinson’s Disease" @default.
- W2347150527 cites W1502339857 @default.
- W2347150527 cites W1540417297 @default.
- W2347150527 cites W1547047969 @default.
- W2347150527 cites W1637252807 @default.
- W2347150527 cites W1645547702 @default.
- W2347150527 cites W1700865237 @default.
- W2347150527 cites W1822826315 @default.
- W2347150527 cites W1900959796 @default.
- W2347150527 cites W1963641716 @default.
- W2347150527 cites W1964705113 @default.
- W2347150527 cites W1967286178 @default.
- W2347150527 cites W1971301285 @default.
- W2347150527 cites W1971669864 @default.
- W2347150527 cites W1971982338 @default.
- W2347150527 cites W1972576882 @default.
- W2347150527 cites W1974240711 @default.
- W2347150527 cites W1974415029 @default.
- W2347150527 cites W1974629517 @default.
- W2347150527 cites W1976864429 @default.
- W2347150527 cites W1980866137 @default.
- W2347150527 cites W1982761758 @default.
- W2347150527 cites W1985415750 @default.
- W2347150527 cites W1985423204 @default.
- W2347150527 cites W1986267411 @default.
- W2347150527 cites W1986491834 @default.
- W2347150527 cites W1987387780 @default.
- W2347150527 cites W1990031349 @default.
- W2347150527 cites W1990898457 @default.
- W2347150527 cites W1990909663 @default.
- W2347150527 cites W1991202463 @default.
- W2347150527 cites W1992401138 @default.
- W2347150527 cites W1993716787 @default.
- W2347150527 cites W1994083390 @default.
- W2347150527 cites W1995711600 @default.
- W2347150527 cites W1997243628 @default.
- W2347150527 cites W1998649401 @default.
- W2347150527 cites W2002917813 @default.
- W2347150527 cites W2003179182 @default.
- W2347150527 cites W2003223142 @default.
- W2347150527 cites W2003705034 @default.
- W2347150527 cites W2007566102 @default.
- W2347150527 cites W2010024285 @default.
- W2347150527 cites W2011148425 @default.
- W2347150527 cites W2013047529 @default.
- W2347150527 cites W2014276094 @default.
- W2347150527 cites W2014439239 @default.
- W2347150527 cites W2014553622 @default.
- W2347150527 cites W2014631778 @default.
- W2347150527 cites W2014932121 @default.
- W2347150527 cites W2015730126 @default.
- W2347150527 cites W2016542068 @default.
- W2347150527 cites W2017010915 @default.
- W2347150527 cites W2019739356 @default.
- W2347150527 cites W2022966746 @default.
- W2347150527 cites W2023243943 @default.
- W2347150527 cites W2023581663 @default.
- W2347150527 cites W2024486693 @default.
- W2347150527 cites W2025946076 @default.
- W2347150527 cites W2032122746 @default.
- W2347150527 cites W2032628032 @default.
- W2347150527 cites W2034624984 @default.
- W2347150527 cites W2035395665 @default.
- W2347150527 cites W2037852973 @default.
- W2347150527 cites W2038505488 @default.
- W2347150527 cites W2043166209 @default.
- W2347150527 cites W2045914012 @default.
- W2347150527 cites W2046592350 @default.
- W2347150527 cites W2048343328 @default.
- W2347150527 cites W2049055721 @default.
- W2347150527 cites W2049451450 @default.
- W2347150527 cites W2050563095 @default.
- W2347150527 cites W2050903686 @default.
- W2347150527 cites W2051720676 @default.
- W2347150527 cites W2052119205 @default.
- W2347150527 cites W2052378705 @default.
- W2347150527 cites W2054372934 @default.
- W2347150527 cites W2055557007 @default.
- W2347150527 cites W2055968207 @default.
- W2347150527 cites W2056189825 @default.
- W2347150527 cites W2056798863 @default.
- W2347150527 cites W2057632749 @default.
- W2347150527 cites W2058544402 @default.
- W2347150527 cites W2058623213 @default.
- W2347150527 cites W2060612860 @default.
- W2347150527 cites W2060885977 @default.
- W2347150527 cites W2061079288 @default.
- W2347150527 cites W2062241212 @default.
- W2347150527 cites W2069082731 @default.